DeLong Mark Jeffrey 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 17, 2024
Insider Transaction Report
Form 4
DeLong Mark Jeffrey
Chief Business & Strat Officer
Transactions
- Award
Common Stock
2024-01-16+16,963→ 68,585 total - Award
Stock Option (Right to Buy)
2024-01-16$66.30/sh+24,666$1,635,356→ 24,666 totalExercise: $66.30Exp: 2034-01-15→ Common Stock (24,666 underlying) - Sale
Common Stock
2024-01-16$66.81/sh−1,631$108,965→ 66,954 total
Footnotes (3)
- [F1]This represents an award of Restricted Stock Units granted 01/16/2024 that vests annually from grant date over a four year period subject to continued service.
- [F2]This represents shares sold to cover tax withholding on the Restricted Stock Units released on 01/12/2024.
- [F3]This represents a stock option award granted 01/16/2024 that vests over a four year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.